2020
DOI: 10.4193/rhin20.601
|View full text |Cite
|
Sign up to set email alerts
|

Executive Summary of EPOS 2020 Including Integrated Care Pathways

Abstract: The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 is the update of similar evidence based position papers published in 2005 and 2007 and 2012 (1-3). The core objective of the EPOS2020 guideline is to provide revised, up-to-date and clear evidence-based recommendations and integrated care pathways in ARS and CRS. EPOS2020 provides an update on the literature published and studies undertaken in the eight years since the EPOS2012 position paper was published and addresses areas not extensively c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
255
0
41

Year Published

2020
2020
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 303 publications
(298 citation statements)
references
References 130 publications
(158 reference statements)
2
255
0
41
Order By: Relevance
“…The heterogeneity of disease endotypes, the time-consuming and costly nature of primary epithelial cultures, and challenges in interpretation of in vitro study results 67 or translating murine findings to human diseases have all resulted in the lack of inclusion of nasal and bronchial epithelial barrier function in the guidelines for diagnostic work-out of patients affected by (allergic) rhinitis, CRS, and/or asthma. 68 The lack of commercially available tools to diagnose epithelial barrier dysfunction in the human airways, and the limited knowledge on the function of distinct epithelial cells, hampers the implementation of the airway epithelial barrier in clinical practice.…”
Section: Epithelial Leakiness and Pathologymentioning
confidence: 99%
“…The heterogeneity of disease endotypes, the time-consuming and costly nature of primary epithelial cultures, and challenges in interpretation of in vitro study results 67 or translating murine findings to human diseases have all resulted in the lack of inclusion of nasal and bronchial epithelial barrier function in the guidelines for diagnostic work-out of patients affected by (allergic) rhinitis, CRS, and/or asthma. 68 The lack of commercially available tools to diagnose epithelial barrier dysfunction in the human airways, and the limited knowledge on the function of distinct epithelial cells, hampers the implementation of the airway epithelial barrier in clinical practice.…”
Section: Epithelial Leakiness and Pathologymentioning
confidence: 99%
“…Glucocorticoids, such as dexamethasone, are drugs used for the first-line treatment of CRS with NPs to suppress nasal inflammation. 3 The clinical efficacy of glucocorticoids for treating NPs results from the induction of apoptosis in both eosinophils and T-lymphocytes that infiltrate NPs and the downregulation of epithelial GM-CSF production, which prolongs eosinophil survival. 4…”
Section: Discussionmentioning
confidence: 99%
“…Glucocorticoids, including dexamethasone, are the most widely prescribed antiinflammatory drugs and are the only currently available treatment option with proven efficacy for NPs. 3 According to previous reports, glucocorticoids increase apoptosis in various inflammatory cells including eosinophils, fibroblasts, and nasal epithelial cells. [4][5][6] Estrogen (17β-estradiol) is known to regulate the expression of genes involved in cell survival, proliferation, differentiation, and reproduction, 7 through binding to its receptors (ERs), ER-α, ER-β.…”
Section: Introductionmentioning
confidence: 93%
“…The sample comprised 48 individuals with a European Position (EPOS) 2012 13 diagnosis of NP, and 15 healthy controls for comparison of the baseline TGF-β1 levels in the peripheral blood.…”
Section: Methodsmentioning
confidence: 99%